Aim To determine the value of IFN (intzerferon)-α in the patients with systemic lupus erythematosus (SLE) and to correlate IFN-α with values of non-specific biochemical parameters of inflammation (C-reactive protein, leukocytes values, erythrocyte sedimentation rate, albumins and globulins). Methods Research included 55 patients with SLE diagnosis and a control group consisted of 25 healthy subjects (during period 2019-2020). IFN (Interferon)-α and non-specific biochemical parameters of inflammation were obtained using standard protocols. Results IFN-α values were independent of gender (p=0.95). The difference in serum IFN-α values in relation with the age in the SLE group was statistically significant (p=0.036). Only serum globulin was significantly higher (p=0.0023) in IFN-α positive compared to IFN-α negative SLE patients. A statistically significant correlation between the values of IFN-α and globulin was proved (r=0.315; p=0.019). No significant correlation was found between other non-specific biochemical parameters and IFN-α values. Conclusion Increased IFN-α values were observed in younger patients, and the correlation between IFN and globulin was proved.
He S, Tang C, Yu J, Ma J, Qiao M, Zhou W, et al. Combining C reactive protein and serum albumin to predict 90-day mortality in systemic lupus erythematosus with serious community-acquired infections. Lupus Sci Med. 2021;505.
2.
Almaghlouth I, Johnson S, Pullenayegum E, Gladman D, Urowitz M. Immunoglobulin levels in systemic lupus erythematosus: a narrative review. Lupus. 2021;867–75.
3.
Draborg A, Lydolph M, Westergaard M, Larsen O, Nielsen S, Duus C, et al. Elevated concentrations of serum immunoglobulin free light chains in systemic lupus erythematosus patients in relation to disease activity, inflammatory status, B cell activity and Epstein-Barr virus antibodies. PLoS One. 2015;138753.
4.
Eudy A, Vines A, Dooley M, Cooper G. Parks CG. Elevated C-reactive protein and self-reported disease activity in systemic lupus erythematosus. Lupus. 2014;1460–7.
5.
Riboldi P, Gerosa M, Moroni G, Radice A, Allegri F, Sinico A, et al. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus. Autoimmunity. 2005;39–45.
6.
Lee J, Park J, Lee E, Lee E, Song Y. Circulating exosomes from patients with systemic lupus erythematosus induce a proinflammatory immune response. Arthritis Res Ther. 2016;264.
7.
Ito T, Kanzler H, Duramad O, Cao W, Liu Y. Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells. Blood. 2006;2423–31.
8.
Abida R, Yeoh S, Isenberg D. Advances in systemic lupus erythematosus. Medicine. 2022;7–17.
9.
Kirou K, Gkrouzman E. Anti-interferon alpha treatment in SLE. Clin Immunol. 2013;303–12.
10.
Reizis B, Colonna M, Trinchieri G, Barrat F, Gilliet M. Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system? Nat Rev Immunol. 2011;558–65.
11.
Cucak H, Yrlid U, Reizis B, Kalinke U, Johansson-Lindbom B. Type I interferon signaling in dendritic cells stimulates the development of lymph-noderesident T follicular helper cells. Immunity. 2009;491–501.
12.
Niewold T, Clark D, Salloum R, Poole B. Interferon alpha in systemic lupus erythematosus. J Biomed Biotechnol. 2010;948364.
13.
Mathian A, Koutouzov S. Interferon-alpha: a key cytokine in systemic lupus erythematosus pathogenesis. Rev Med Interne. 2008;696–700.
14.
Hernández-Martínez A, Gavilán-Carrera B, Vargas-Hitos J, Morillas-De-Laguno P, Sola-Rodríguez S, Rosales-Castillo A, et al. Ideal cardiovascular health in women with systemic lupus erythematosus: association with arterial stiffness, inflammation, and fitness. Int J Cardiol. 2021;207–13.
15.
Connelly K, Morand E. Systemic lupus erythematosus: a clinical update. Intern Med J. 2021;1219–28.
16.
Enocsson H, Gullstrand B, Eloranta M, Wetterö J, Leonard D, Rönnblom L, et al. C-reactive protein levels in systemic lupus erythematosus are modulated by the interferon gene signature and CRP gene polymorphism rs1205. Front Immunol. 2021;622326.
17.
Vaillant J, Goyal A, Bansal A, Varacallo P, M. Systemic Lupus Erythematosus Treasure Island. 2021;
18.
Barber M, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow N, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;515–32.
19.
Uzkeser H, Keskin H, Haliloglu S, Cayir Y, Karaaslan Y, Kosar A, et al. Is mean platelet volume related to disease activity in systemic lupus erythematosus? Int J Clin Pract. 2021;e14676.
20.
Rubio J, Kyttaris V. Measuring IFN activity in suspected SLE: a valuable step? Expert Rev Clin Immunol. 2021;545–8.
21.
Rönnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med. 2019;270.
22.
Wittling M, Cahalan S, Levenson E, Rabin R. Shared and unique features of human interferon-beta and interferon-alpha subtypes. Front Immunol. 2021;605673.
23.
Chasset F, Arnaud L. Targeting interferons and their pathways in systemic lupus erythematosus. Autoimmun Rev. 2018;44–52.
24.
Table 1. Non-specific biochemical parameters of inflammation in relation to IFN-α values in patients with systemic lupus erythematosus (SLE).
25.
Erythrocyte sedimentation rate (mm ⁄h).
26.
Leukocytes.
27.
Idborg H, Oke V. Parameter IFN-α. Int J Mol Sci. 2021;11327.
28.
Sarwar S, Mohamed A, Rogers S, Sarmast S, Kataria S, Mohamed K, et al. Neuropsychiatric systemic lupus erythematosus: a 2021 update on diagnosis, management, and current challenges. Cureus. 2021;17969.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
